Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

8.6K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

6.4K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
6.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

The New England journal of medicine·2026
Same author

Immunotherapy in pediatric bone sarcomas: Current progress and future directions.

Human vaccines & immunotherapeutics·2026
Same author

Clinicopathologic features and prognostic factors in hepatic epithelioid hemangioendothelioma.

Annals of diagnostic pathology·2026
Same author

Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.

Journal of kidney cancer and VHL·2026
Same author

PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

Blood advances·2026
Same author

The seventh kidney cancer research summit: progress in accelerating cures.

The oncologist·2026
Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026
Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026
Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026
Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026
Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026
Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

11.9K

WT1 regulates angiogenesis in Ewing Sarcoma.

Varalakshmi Katuri1, Stephanie Gerber, Xiaofei Qiu

  • 1Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.

Oncotarget
|May 10, 2014
PubMed
Summary
This summary is machine-generated.

Wilms Tumor 1 (WT1) protein regulates tumor angiogenesis, a key process for tumor growth. This study shows WT1 controls expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic genes in Ewing sarcoma.

More Related Videos

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.7K
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.2K

Related Experiment Videos

Last Updated: Apr 30, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

11.9K
Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.7K
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor growth necessitates angiogenesis, the formation of new blood vessels.
  • Vascular Endothelial Growth Factor (VEGF) is a critical mediator of angiogenesis.
  • The Wilms Tumor 1 (WT1) protein influences mRNA transcription and splicing, and regulates VEGF expression.

Purpose of the Study:

  • To investigate the role of WT1 as a regulator of tumor angiogenesis in Ewing sarcoma.
  • To determine if WT1 controls the expression of pro-angiogenic factors in Ewing sarcoma.

Main Methods:

  • Expressed exogenous WT1 in WT1-null Ewing sarcoma cells (SK-ES-1).
  • Suppressed WT1 using short hairpin RNA (shRNA) in WT1-positive Ewing sarcoma cells (MHH-ES).
  • Analyzed expression of WT1, VEGF, and other pro-angiogenic molecules (MMP9, Ang-1, Tie-2) in cell lines and primary tumor samples.

Main Results:

  • WT1 suppression in MHH-ES cells impaired angiogenesis.
  • WT1 expression in SK-ES-1 cells increased angiogenesis.
  • WT1 isoforms differentially affected vessel morphology and VEGF isoform expression.
  • WT1-expressing tumors showed elevated levels of VEGF, MMP9, Ang-1, and Tie-2.
  • WT1 expression correlated with VEGF, MMP9, and microvessel density in primary Ewing sarcoma.

Conclusions:

  • WT1 is a key regulator of tumor angiogenesis in Ewing sarcoma.
  • WT1 directly controls the expression of multiple pro-angiogenic genes, including VEGF.
  • WT1's role in angiogenesis suggests it as a potential therapeutic target in Ewing sarcoma.